Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 22, Issue 4, Pages 2518-2522Publisher
WILEY
DOI: 10.1111/jcmm.13536
Keywords
acute coronary syndrome; aldehyde dehydrogenase 2; Glu504Lys variant; prognosis
Categories
Funding
- Taishan Scholar Program of Shandong Province [ts20130911, tsqn20161065]
- Fundamental Research Funds of Shandong University [2014QLKY04]
- National Natural Science Foundation of China [81571934, 81570401, 81601717]
- Specialized Research Fund for the Doctoral Program of Higher Education [20130131110048]
- Key Technology Research and Development Program of Science and Technology of Shandong Province [2014kjhm0102]
- Science Foundation of Qilu Hospital of Shandong University [2016QLQN02]
- Department of Science and Technology of Shandong Province [2014GSF118111]
Ask authors/readers for more resources
Aldehyde dehydrogenase 2 (ALDH2) Glu504Lys variant was an independent risk factor for acute coronary syndrome (ACS). However, there are lacking researches about the relationship between the variant and prognosis of ACS. In the prospective study, 377 ACS patients were grouped into the wild-type (*1/*1) and the mutation (*2/*2 + *1/*2) groups according to genotype detection. Compared with the wild-type group, incidences of major adverse cardiac events (MACE) and cardiac death were both higher in the mutation group (9.2% vs 21.0%, P = .002; 5.2% vs 12.2%, P = .026); the MACE-free and the cardiac-death-free cumulative survival rates were obviously lower in the mutation group. Moreover, the mutant genotypes were associated with significantly increased risk of MACE and cardiac death (HR 2.443, 95%CI: 1.390-4.296, P = .002; HR 2.727, 95%CI: 1.303-5.708, P = .008). These results suggested that ALDH2 Glu504Lys variant could predict a worse prognosis of ACS patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available